Ischemic heart disease is the principal cause of death worldwide and clinically manifests as
myocardial infarction (MI), stable angina, and ischemic cardiomyopathy. Myocardial …

Osteoprotegerin (OPG) is a glycoprotein involved in the regulation of bone remodelling.
OPG regulates osteoclast activity by blocking the interaction between the receptor activator …

Aims The aim of this study was to determine microvascular function in the acute phase of
Takotsubo syndrome (TTS) and to identify inflammatory mediators that could reflect TTS …

Aims This study investigates the role of osteoprotegerin (OPG) and growth‐differentiation
factor 15 (GDF‐15) as predictors of outcome in cardiogenic shock (CS) complicating acute …

Background: Osteoprotegerin (OPG) is a molecule which belongs to the tumor necrosis
factor receptor superfamily. OPG concentration is elevated in patients with left ventricle …

Aims: Soluble suppression of tumorigenicity 2 (sST2) was validated to independently predict
prognosis for heart failure (HF) and ST-segment elevation myocardial infarction (STEMI). In …

Molecules that govern bone metabolism, such as osteoprotegerin (OPG) and osteopontin
(OPN), have been isolated from other tissues, including blood vessels. Atherosclerosis and …

Results The main groups of assessed biomarkers included B-type natriuretic peptides,
markers of cardiomyocyte injury and necrosis, markers of inflammatory response, markers of …

Background Osteoprotegerin (OPG) is a secretory glycoprotein and participates in the
progression of atherosclerotic lesions. We aim to explore the relationship between OPG and …

Early prediction of significant morbidity or mortality in patients with acute ST-segment
elevation myocardial infarction (STEMI) represents an unmet clinical need. In phenotypically …